Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DTRMWXHS 12

Next Previous
Drug Profile

DTRMWXHS 12

Alternative Names: DTRM-12; DTRMWXHS12

Latest Information Update: 22 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang DTRM Biopharma
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • No development reported B-cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 31 Dec 2024 Zhejiang DTRM Biopharma terminates a phase II trial in in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) due to lack of necessary financial resources to continue the trial (NCT04305444)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Mantle-cell-lymphoma(Second-line therapy or greater) in China (PO, Capsule)
  • 17 Nov 2021 Zhejiang DTRM Biopharma completes a phase I/II trial in Mantle-cell lymphoma (In adults, Refractory metastatic disease, Recurrent) in China (PO) (NCT03836768)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top